Trial · NCT07436104
Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.
NCT07436104, Phase 4, Completed, MAHAN Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. Trials, record NCT07436104. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07436104
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.
- NCT number
- NCT07436104
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 72,564 participants, actual
- Lead sponsor
- MAHAN Trust
- Conditions
- Hypertension (HTN), Diarrhea, Pneumonia, Malaria Fever, COPD, Asthma (Diagnosis), Diarrhea Chronic
- Interventions
Trained village health workers (VHWs) , provided treatment of HTN, diarrhoea, malaria, pneumonia, asthma and COPD by Amlodipine, ORS, Norfloxacin, Chloroquine, Azithromycin, salbutamol rotacaps, Appropriate referral
- First posted
- 2026-02-27
- Last updated
- 2026-02-27
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Age specific mortality rate (ASMR) 16 to 60 years age group.Age-specific mortality rate (ASMR) is calculated by dividing number of deaths in particular age group in a calendar year by mid-year population for that age group, multiplied by 100000. | Baseline (Year 2004) to 2023 , annually for up to 19 years | Comparison of change in ASMR (16-60 years) in IA vs CA from baseline to end of the study. The annual midyear population of persons aged 16-60 years was used as denominator for cal-culating ASMR of that year.Two-sample t-test across all yearly ASMR measurements (2005-2015 and 2017-2022) between arms was done to measure overall difference in mortality levels (treating each year's cluster-level ASMR as an independent observation). Simple linear regression of ASMR against year for each arm was performed for evaluation over time and comparison of the slope coefficients (trend in intervention vs control). The relative risk ratios (RRR)/ mortality rate ratio (MRR) was ob-tained for each study year to understand the effect of intervention as compared to control. Risk ratio (RR) were obtained in each arm as a ratio of number of deaths in one/two years to the mid-year population in 16-60 years group of respective years. Relative risk ratio (RRR) were obtained as a ratio of RR of IA v |
| Secondary | Disease/cause specific mortality rate.Total no. of deaths (in the age group of 16-60 years) in one year due to one particular disease multiplied by 100000 and divided by total No. of people in the age group of 16 to 60 years in that year. | Annual from 2004 to 2014. | Reduction in disease-specific mortality rates because of diarrhoea, malaria, pneumonia, asthma, COPD, tuberculosis and cardio-vascular diseases (CVDs), in IA from baseline to end of re-search phase. Diarrhea specific mortality rate is total no. of deaths (in the age group of 16-60 years) in one year due to diarrhea multiplied by 100000 and divided by total No. of people in the age group of 16 to 60 years in that year. Malaria specific mortality rate is total no. of deaths (in the age group of 16-60 years) in one year due to Malaria multiplied by 100000 and divided by total No. of people in the age group of 16 to 60 years in that year. Pneumonia specific mortality rate is total no. of deaths (in the age group of 16-60 years) in one year due to Pneumonia multiplied by 100000 and divided by total No. of people in the age group of 16 to 60 years in that year. Similarly for other cause specific mortality rates. |
| Secondary | Efficacy of village health workers ( VHWs). Community based program delivered through VHW is effective for reducing adult mortality or not. | Years: Baseline year to year of end of study . (Research phase: 11 years, replication phase: 7 years). | The efficacy of VHWs will be determined by following indicators. 1)Difference in difference (DID) of change in ASMR from baseline to endline in the IA versus CA and whether it is statistically significant or not. If the difference is significant , then VHWs' interventions are effective. The trends in the Relative Risk Ratio (RRR) of ASMR (16-60 years) for the IA and the CA over time, with 95% confidence intervals (CIs), obtained during study phases are significant if RRR is \<1 during the intervention periods. If the treatment group of intervention arm has significant reduction in CSMR than no-treatment group from IA only, from baseline to study end , then the interventions by VHWs are effective. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07436104
GET https://conductscience.org/api/trials/v1/NCT07436104/registered